Ameritas Investment Partners’s Natus Medical Inc NTUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-2,645
Closed -$86K 3069
2022
Q2
$86K Hold
2,645
﹤0.01% 1621
2022
Q1
$70K Hold
2,645
﹤0.01% 1865
2021
Q4
$63K Hold
2,645
﹤0.01% 1992
2021
Q3
$66K Hold
2,645
﹤0.01% 1978
2021
Q2
$69K Sell
2,645
-374
-12% -$10.2K ﹤0.01% 1971
2021
Q1
$77K Hold
3,019
﹤0.01% 1816
2020
Q4
$61K Hold
3,019
﹤0.01% 1871
2020
Q3
$52K Hold
3,019
﹤0.01% 1818
2020
Q2
$66K Hold
3,019
﹤0.01% 1674
2020
Q1
$70K Buy
3,019
+210
+7% +$6.1K ﹤0.01% 1475
2019
Q4
$93K Hold
2,809
﹤0.01% 1561
2019
Q3
$89K Hold
2,809
﹤0.01% 1544
2019
Q2
$72K Hold
2,809
﹤0.01% 1702
2019
Q1
$71K Hold
2,809
﹤0.01% 1690
2018
Q4
$96K Hold
2,809
0.01% 1414
2018
Q3
$100K Hold
2,809
﹤0.01% 1573
2018
Q2
$97K Hold
2,809
﹤0.01% 1573
2018
Q1
$95K Hold
2,809
﹤0.01% 1520
2017
Q4
$107K Hold
2,809
﹤0.01% 1469
2017
Q3
$94K Hold
2,809
﹤0.01% 1501
2017
Q2
$105K Hold
2,809
0.01% 1437
2017
Q1
$110K Buy
+2,809
New +$105K 0.01% 1372

Other funds holding NTUS

Ameritas Investment Partners's NTUS Position: Q3 2022 in Review

Ameritas Investment Partners sold out of Natus Medical Inc (NTUS) in Q3 2022, closing a stake of 2,645 shares — an estimated $86K sold.

Ameritas Investment Partners first reported a position in NTUS in Q1 2017 and held it in 22 quarters. The position peaked at $110K in Q1 2017. 1 fund tracked by Wall St. Rank holds NTUS as of Q3 2022.

  • Ameritas Investment Partners reported no remaining Natus Medical Inc position as of Q3 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 2,645 Natus Medical Inc shares in Q3 2022, an estimated $86K.
  • Ameritas Investment Partners first reported a position in Natus Medical Inc in Q1 2017 and held it in 22 quarters.
  • Ameritas Investment Partners's Natus Medical Inc position peaked at $110K in Q1 2017.
  • 1 fund tracked by Wall St. Rank held Natus Medical Inc as of Q3 2022.

Based on Ameritas Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.